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Background: Acute posthypoxic myoclonus (PHM) can occur in patients admitted after cardiopulmonary
resuscitation (CPR) and is considered to have a poor prognosis. The origin can be cortical and/or subcortical and
this might be an important determinant for treatment options and prognosis. The aim of the study was to
investigate whether acute PHM originates from cortical or subcortical structures, using somatosensory evoked
potential (SEP) and electroencephalogram (EEG).
Methods: Patients with acute PHM (focal myoclonus or status myoclonus) within 72 hours after CPR were
retrospectively selected from a multicenter cohort study. All patients were treated with hypothermia. Criteria for
cortical origin of the myoclonus were: giant SEP potentials; or epileptic activity, status epilepticus, or generalized
periodic discharges on the EEG (no back-averaging was used). Good outcome was defined as good recovery or
moderate disability after 6 months.
Results: Acute PHM was reported in 79/391 patients (20%). SEPs were available in 51/79 patients and in 27 of them
(53%) N20 potentials were present. Giant potentials were seen in 3 patients. EEGs were available in 36/79 patients
with 23/36 (64%) patients fulfilling criteria for a cortical origin. Nine patients (12%) had a good outcome. A broad
variety of drugs was used for treatment.
Conclusions: The results of this study show that acute PHM originates from subcortical, as well as cortical
structures. Outcome of patients admitted after CPR who develop acute PHM in this cohort was better than
previously reported in literature. The broad variety of drugs used for treatment shows the existing uncertainty
about optimal treatment.
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Many patients remain comatose after successful cardio-
pulmonary resuscitation (CPR) due to brain damage
caused by hypoxemia. Acute posthypoxic myoclonus
(PHM) occurs in about 19-37% of these patients, typic-
ally within the first 24 hours after CPR, but knowledge
about this illness is limited [1,2]. Acute PHM can be
divided into status myoclonus and (multi)focal myoclo-
nus. In daily practice different terms are used for status* Correspondence: a.bouwes@amc.uva.nl
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reproduction in any medium, provided the ormyoclonus, e.g. generalized myoclonus, myoclonus sta-
tus, or myoclonic status epilepticus [1,3,4]. Wijdicks
et al. defined status myoclonus as spontaneous or
sound-sensitive, repetitive, irregular brief jerks in both
face and limb present during most of the first day after
CPR [1]. Specific EEG criteria were not mentioned. Focal
myoclonus, such as platysmal myoclonus has also been
reported in patients after CPR [4]. Most studies concern-
ing acute PHM were performed before treatment with
hypothermia after CPR was implemented. Nowadays,
acute PHM is often suppressed during the first day after
admission by the administration of sedative drugs or
neuromuscular blocking agents during hypothermia
treatment. Stimulus sensitive myoclonus often interferes
with nursing of these patients, is deterrent to relatives,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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treatment exist [5-7]. Lance-Adams syndrome, chronic
PHM, also occurs in patients after CPR, but usually
arises in the post-intensive care unit period and it is
mainly seen after hypoxia as primary cause of CPR [5,8].
Based on clinical and electrophysiological features, one
can discriminate between a cortical and subcortical ori-
gin of myoclonus. Clinically, cortically generated myo-
clonus is mostly focal or multifocal and mainly affects
parts of the body with a large cortical representation,
such as hand and face. Subcortical myoclonus, especially
reticular myoclonus, is generalized, predominantly
affecting axial and proximal limbs. Both types of myo-
clonus can be stimulus sensitive [6,9-11]. Neurophysio-
logic investigations such as somatosensory evoked
potential (SEP), electroencephalogram (EEG), electro-
myography (EMG), and EEG-EMG with back-averaging
enable localization of the origin of myoclonus. Giant
potentials on SEP recordings and epileptiform discharges
or sharp/slow waves on the EEG suggest a cortical origin
of the myoclonus [9,12,13]. In case of a subcortical ori-
gin of myoclonus, SEP is normal and there are no con-
sistent abnormalities seen on the EEG [9,13].
The pathophysiology of acute PHM is poorly under-
stood [4,5,11]. Literature suggests that acute PHM origi-
nates from subcortical and/or cortical structures [5,11].
A histological study in 15 patients with status myoclonus
after CPR and 11 patients without myoclonus showed
significantly more neuronal loss in all cortical laminae in
patients with myoclonus, the extent of anoxic-ischemic
damage in the hippocampus and cerebellum was similar
in both patient groups [1].
For optimal treatment in patients with acute PHM,
discrimination between cortical and subcortical origin of
myoclonus would be helpful. Cortical myoclonus is
primarily treated with levetiracetam or piracetam; sub-
cortical myoclonus is usually treated with clonazepam
[5-7,14].
The aim of this study was to investigate the origin of
acute PHM in patients after CPR by retrospectively ana-
lyzing SEP and EEG recordings.
Methods
Data were collected from the database of the prospective
multicenter cohort study PROgnosis after PostAnoxic
Coma II (PROPAC II study) [15]. In the PROPAC II
study 391 adult patients admitted after CPR were
included between December 2007 and August 2009. All
patients were treated with hypothermia. The research
protocol and consent procedures of the PROPAC II
study were approved by the medical ethics committees
of the Academic Medical Center (NL19644.018.07) and
all collaborating hospitals: Medical Center Leeuwarden,
Onze Lieve Vrouwe Gasthuis, St. Antonius Hospital,Rijnstate Hospital, Medical Center Alkmaar (METC
Noord-Holland), Kennemer Gasthuis (METC Noord-
Holland), Spaarne Hospital (METC Noord-Holland),
Reinier de Graaf Groep (METC Zuidwest Holland), and
Sint Lucas Andreas Hospital. Informed consent was
obtained from a legal representative shortly after the
patient’s hospital admission. When the patient regained
consciousness and was able to judge the situation prop-
erly, informed consent was also obtained from the patient.
For the present study, patients reported to have focal
myoclonus or status myoclonus at 24–48 and/or 48–72
hours after CPR were considered to have acute PHM.
Data from those patients were retrieved from the data-
base. Myoclonus was scored on the case record form
with no further differentiation of the severity and clinical
characteristics; there was no score option for multifocal
myoclonus. Patients who were scored to have both focal
myoclonus and status myoclonus were considered to
have status myoclonus. The following variables were
used: gender, age, presenting cardiac rhythm, time to re-
turn of spontaneous circulation, medical history of epi-
lepsy, use of sedative drugs or neuromuscular blocking
agents during SEP.
Neurologic outcome was assessed with the Glasgow
Outcome Scale (GOS) after six months [16]. Good out-
come was defined as GOS 4–5 (good recovery or moder-
ate disability). At the time of data collection for this
study, survivors were contacted by phone and asked if
any form of myoclonus persisted.
Neurologic examination, including the motor score
was performed 48 and 72 hours after CPR. In the PRO-
PAC II study, cortical N20 responses of median nerve
SEP were recorded with standard procedures during
office hours in patients who remained comatose after
regaining normal body temperature [17]. For this study,
SEP recordings were retrieved and assessed by JK. The
SEP was documented as absent (bilaterally absent cor-
tical N20 responses after left and right median nerve
stimulation, with present cervical potential), present
(cortical N20 response present on at least one side) or
undeterminable (technically insufficient recording). If
the N20 was present, the amplitudes of the P27/N35
potentials (after right sided stimulation) were scored
as < 2 μV, 2–5 μV or > 5 μV. Left-right differences were
scored. Giant potentials were defined as a P27/N35
potential > 5 μV. Absent SEPs were not further analyzed.
An EEG was not a standard examination for the PRO-
PAC II study and therefore subject to physicians’ deci-
sion. Available EEG recordings were retrieved and
evaluated by JH, all EEGs were recorded during nor-
mothermia. Presence of epileptic activity, status epilepti-
cus, generalized periodic discharges, burst suppression,
isoelectric/low voltage activity (< 20 μV), and back-
ground reactivity were scored.
Table 1 Baseline characteristics
Total number of patients, n 79
Age, y, mean (SD) 67 (13)
Male, n (%) 58 (73)
Initial rhythm, n (%)
VF/VT 52 (66)
Other 26 (33)
Unknown 1 (1)
Primary cause of CPR, n (%)
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myoclonus were giant SEP potentials or epileptic activ-
ity, status epilepticus, or generalized periodic discharges
on the EEG.
Medication administered for myoclonus or epileptic
seizures was reported 48 and 72 hours after CPR and
categorized as: sodium valproate, clonazepam, other
benzodiazepines, phenytoin, levetiracetam, and propofol.
The clinical effect of the administered drugs was not
evaluated.Cardiac 55 (70)
Hypoxic 8 (10)
Unknown 10 (13)
Missing 6 (8)
Time from collapse to BLS, min, median, (IQR) 5 (1–10)Statistical analysis
Patient characteristics were summarized using descrip-
tive statistics. Variables were expressed as mean and
standard deviation, or when not normally distributed, as
medians and inter-quartile ranges.Time to ROSC, min, median (IQR) 15 (10–25)
Medical history of epilepsy, n (%)
Yes 2 (3)
No 77 (97)
GOS after 6 months, n (%)
1 Death 67 (85)
2 Vegetative state 0 (0)
3 Severe disability 1 (1)
4 Moderate disability 2 (3)
5 Good recovery 7 (9)
Unknown 2 (3)
SD= standard deviation, CPR = cardiopulmonary resuscitation, VF = ventricular
fibrillation, VT = ventricular tachycardia, BLS = Basic Life Support, ROSC = return
of spontaneous circulation, IQR = interquartile range, GOS =Glasgow Outcome
Scale.
Table 2 Acute posthypoxic myoclonus
Focal
myoclonus, n
(%) Status
myoclonus, n
(%) Total,
n
Present 24–48 h 44 (66) 23 (34) 67
Present 48–72 h 23 (55) 19 (45) 42
Present 24–48 h
and 48–72 h
20 (67) 10 (33) 30Results
In 79 of 391 (20%) patients, acute PHM (focal or status
myoclonus) was reported by the physicians in the first
72 hours after CPR. The baseline characteristics and
neurologic outcome are shown in Table 1. A good
neurologic outcome was found in 9/77 (12%) patients
after 6 months. Two patients were lost to follow-up. In
these two patients, 1 month follow-up showed a good
recovery in one and moderate disability in the other.
There was a primary cardiac cause of CPR in 8/9
patients with a good outcome, from one patient the
cause of CPR was missing. Almost all patients with a
poor outcome died, one patient remained severely dis-
abled. In the first 24–48 hours acute PHM was found in
67 patients. In 30/67 (45%) patients, acute PHM per-
sisted at 72 hours after CPR (Table 2). Twelve additional
patients developed acute PHM between 48 and 72 hours.
In the majority of the patients, acute PHM was reported
as focal myoclonus (47/79 patients (59%)), of whom 8
patients (17%) had a good outcome. Status myoclonus
was reported in 32/79 patients (41%), 1 patient survived
and made a good recovery. We were able to contact 5 of
all 10 survivors by phone, one patient reported that focal
myoclonus in the oral and orbital region persisted, even
at 21 months after CPR. The remaining four patients
had no persistent myoclonus.
In 64/79 (81%) acute PHM patients, electrophysio-
logical studies were performed. SEP was recorded after
rewarming in 51 (65%) patients. The results are shown
in Table 3. The majority of the patients had present
SEPs, only 3 patients had a giant potential on the
recordings. Sixty-three percent of the patients received
medication during SEP recordings. The three patients
with a giant SEP potential received phenytoin, or levetir-
acetam in combination with sodium valproate or
phenytoin.A total of 36 EEGs were made, results are shown in
Table 4. In 23 patients (64%) EEG criteria for a cortical
origin were fulfilled. Epileptiform activity and/or status
epilepticus were seen in 18/36 patients (50%). Nine
EEGs showed generalized periodic discharges; in 4 also
epileptiform activity was seen. Only 2 patients had a
burst-suppression pattern on the EEG, both patients had
a reported status myoclonus. No EEGs were performed
in the two patients with known medical history of epi-
lepsy. In two of the three patients with a giant SEP po-
tential, an EEG was performed. One EEG showed
epileptic activity, the other a status epilepticus. Of the
Table 3 Characteristics of the performed somatosensory
evoked potentials
Total number of performed SEPs 51
SEP result n (%)
Present 27 (53)
Absent 19 (37)
Technically undeterminable 5 (10)
Left-right difference
Yes 3 (11)
No 24 (89)
Amplitude P27/N35
< 2 μV 21 (78)
2-5 μV 3 (11)
> 5 μV (giant potential) 3 (11)
SEP =median nerve somatosensory evoked potentials.
Table 5 Treatment of myoclonus
Treatment 48 hours
after CPR,
n = 52
(%) 72 hours
after CPR,
n = 30
(%)
Sodium valproate 14 (27) 5 (17)
Clonazepam 15 (29) 9 (30)
Other benzodiazepines 11 (21) 6 (20)
Phenytoin 15 (29) 11 (37)
Levetiracetam 10 (19) 8 (27)
Propofol 12 (23) 12 (40)
Combination 20 (38) 14 (47)
Unknown 1 (2) 0 (0)
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made a good recovery; none of the EEGs in these
patients showed reactivity of the background, neither
any of the scored EEG characteristics.
The criteria for a cortical origin of the myoclonus were
fulfilled in 24/64 (38%) patients in whom SEP and/or
EEG was performed.Table 4 Characteristics of the performed
electroencephalograms
Total number of performed EEGs 36
Epileptiform activity n (%)
Yes 12 (33)
No 24 (67)
Status epilepticus
Yes 8 (22)
No 28 (78)
Generalized periodic discharges
Yes 9 (25)
No 27 (75)
Burst suppression
Yes 2 (6)
No 34 (94)
Low voltage activity/isoelectric
Yes 2 (6)
No 34 (94)
Background reactivity
Yes 3 (8)
No 30 (83)
Unable to assess 2 (6)
Missing 1 (3)
EEG = electroencephalogram.A broad variety of medication was administered
(Table 5). At 48 and 72 hours, 78% (52/67) and 71% (30/
42) respectively of the acute PHM patients were treated
with any drug. Phenytoin, clonazepam, and propofol
were used most frequently. Less than half of the patients
were treated with a combination of drugs.Discussion
The results of this study show that acute PHM origi-
nates from subcortical, as well as cortical structures; in
38% of the patients, in whom neurophysiologic investi-
gations were performed, strong evidence towards a cor-
tical origin of the myoclonus was found. The limited
clinical information on the signs of myoclonus due to
the retrospective character of the study limits further
conclusions. Our data also suggest that the outcome in
patients with myoclonus after CPR, irrespective of their
origin, is not invariably correlated with poor outcome as
previously described in literature.
To determine the origin of myoclonus, EEG and SEP
recordings were used in this study. Only a very small
number of patients had a giant SEP potential. A giant
SEP potential is compatible with hyperexcitability of the
sensorimotor cortex and proves the cortical origin of
myoclonus. These giant SEPs are especially found in
patients with progressive myoclonic epilepsy. However,
absence of a giant SEP potential does not rule out a cor-
tical origin of the myoclonus [13]. A reason for the low
number of giant potentials of SEPs could be the flatten-
ing effect of different antiepileptic drugs, such as clona-
zepam, levetiracetam and sodium valproate on the
amplitude of the giant SEP response [18-20]. Many
patients in our study were treated with these types of
drugs during SEP registration, which probably has led to
an underestimation of a cortical origin.
Various EEG patterns in acute PHM patients are
described in the literature; epileptic activity or sharp/
slow waves on the EEG may suggest cortical origin, but
does not proof it [9,12,13]. In 64% of the EEGs in our
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ity, status epilepticus, or generalized periodic discharges
were seen [9]. Furthermore, bursts of generalized spikes
and polyspikes or a burst suppression pattern are often
found on EEG, which is thought to be consistent with
severe neuronal injury [5]. Previous studies described a
burst suppression pattern in 50-84% of patients with sta-
tus myoclonus [1,3,4]. In our study, only 2/32 patients
with status myoclonus had a burst suppression pattern.
A possible explanation might be that the EEGs in our
study were performed at different intervals after admis-
sion, which was previously studied by Thömke et al.. He
showed that specific EEG-patterns in comatose patients
with generalized myoclonus after CPR are often transi-
ent and change over time [3].
Rossetti et al. showed in a prospective cohort study of
patients admitted after cardiac arrest and treated with
hypothermia that 3/56 patients without EEG background
reactivity survived until hospital discharge. None of
these patients had a good outcome after 3–6 months
[21]. On the contrary with these findings, none of the 3
patients with EEG recordings and good outcome in our
study showed background reactivity.
A study limitation was that the performance of an
EEG was subject to physicians’ decision. In The Nether-
lands, SEPs are usually performed before EEGs are
requested and in case of bilaterally absent cortical N20
responses, the majority of the physicians will withdraw
supportive ICU treatment, so no further investigations
are performed [22]. This could have led to selection bias
of patients in whom EEG was performed and it is pos-
sible that our results underestimate some of the EEG
patterns in this type of patients.
In general, the outcome in our acute PHM population
was better than expected based on previous publications.
Several cohort studies before and after the introduction
of therapeutic hypothermia after CPR reported survival
rates of 0-11% for patients with acute posthypoxic myo-
clonus or myoclonic status epilepticus, with poor out-
come for all survivors [1,3,4,23-27]. Two studies from
the 1980s of Celesia et al. and Levy et al. have reported
independent functioning rates similar to our study, in 1/
13 (8%) and 2/21 (10%) patients respectively [28,29]. Re-
cently, two studies in patients with myoclonus after car-
diac arrest and treatment with hypothermia showed a
good outcome in 3-10% [21,30]. A likely explanation for
the difference in mortality between the studies is the
definition used for acute PHM and status myoclonus.
The original definition of status myoclonus by Wijdicks
et al. included revelation within 24 hours. Nowadays,
acute PHM might be suppressed during hypothermia
treatment due to administration of sedative drugs. An-
other possible explanation might be the limited number
of patients with myoclonus in the studies.Acute PHM is difficult to treat and knowledge about
the origin in the brain could probably lead to better
treatment and identification of patients with a more
favourable outcome. In our study, various drugs were
used for the treatment of acute PHM. This reflects the
uncertainty about the best treatment for this syndrome
[5,14]. In general, cortical myoclonus is primarily treated
with levetiracetam or piracetam; subcortical myoclonus
is usually treated with clonazepam [5-7,14]. Treatment
with phenytoin, sodium valproate, phenobarbital or vari-
ous benzodiazepines is often ineffective [1,3,25]. Propo-
fol causes enhancement of gamma-amino butyric acid
and has been successfully used as treatment of acute
PHM [25,31].
A study limitation is the retrospective method used to
select patients from the PROPAC II study, which was
designed to establish the validity of diagnostic methods
to predict poor outcome in patients treated with mild
hypothermia after CPR. The fact that not in all patients
neurophysiologic tests were performed is also a limita-
tion and might limit robust conclusions from this study.
A study primarily investigating acute PHM should
ideally contain video recording of the myoclonus in each
patient, evaluation by blinded assessors and strict evalu-
ation of the effect of standardized medication used. Fur-
thermore, it should combine EEG and SEP recordings
with EEG-EMG with back-averaging, as this last method
can prove a cortical origin [13]. Future research with the
above mentioned standardized observation techniques,
more neurophysiologic tests, and randomized treatment
groups are necessary to evaluate the effect of different
treatment strategies.Conclusions
Despite the limitations mentioned above we think that
acute PHM originates from subcortical, as well as cor-
tical structures and that the outcome of patients admit-
ted after CPR who develop acute PHM might be better
than previously reported. The broad variety of drugs
used for treatment shows the existing uncertainty about
optimal treatment.
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